39 completed, 4 active not recruiting, 4 recruiting, 2 unknown. 53 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 53 | Completed 39, Active not recruiting 4, Recruiting 4, Unknown 2, Withdrawn 2, Not yet recruiting 1, Terminated 1 |
Follow Neisseriaceae Infections: new trials by email Literature Review of Neisseriaceae Infections trials Research Report on Neisseriaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 Years MPSV-ACYW - Meningococcal Disease; Meningococcal Meningitis | Phase 4 | Not yet recruiting | Zhejiang Provincial Center for Disease Control and Prevention | 200 | 2026-10-20 | 2026-10-21 |
| Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Doxycycline hyclate delayed released 200 mg, Doxycycline hyclate delayed released 200 mg weekly, Per standard of care with quarterly STI testing/treatment and sexual health counseling - Gonorrhea, Chlamydia | Phase 4 | Recruiting | Westat | 760 | 2026-02-27 | 2026-10-16 |
| Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM WHO-recommended periodic presumptive treatment, Doxycycline post-exposure prophylaxis - Gonorrhea Male, Chlamydia (Male) | Phase 4 | Active not recruiting | University of Washington | 2900 | 2025-10-29 | 2026-11-02 |
| The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand. Doxycycline (200mg/day) - Syphilis Infection, Gonorrhea | Phase 4 | Recruiting | Bangrak STIs Center | 400 | 2025-10-06 | 2026-02-09 |
| Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM DoxyODPrEP, DoxyPEP - Sexually Transmitted Diseases, Bacterial, Syphilis | Phase 4 | Active not recruiting | Chinese University of Hong Kong | 300 | 2025-03-29 | 2026-06-05 |
| Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons Serogroup B meningococal vaccine - Meningococcal Meningitis, Serogroup B, Transgender Persons | Phase 4 | Recruiting | University Ghent | 250 | 2025-01-31 | 2026-01-20 |
| Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants MCV4 - Epidemic Meningitis | Phase 4 | Completed | CanSino Biologics Inc. | 3011 | 2024-06-12 | 2026-08-13 |
| A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age rMenB+OMV NZ - Meningitis, Meningococcal | Phase 4 | Active not recruiting | GlaxoSmithKline | 50 | 2023-11-10 | 2026-04-06 |
| Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) MCV4 - Epidemic Meningitis | Phase 4 | Active not recruiting | CanSino Biologics Inc. | 660 | 2023-09-20 | 2026-03-04 |
| Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline Doxycycline, Ceftriaxone, benzathine penicillin G - Early Syphilis | Phase 4 | Terminated | National Taiwan University Hospital | 109 | 2023-03-10 | 2026-02-25 |
| Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine - Hiv, Meningococcal Infections | Phase 4 | Recruiting | Thomas Benfield | 55 | 2021-04-28 | 2021-05-06 |
| Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea Cefixime, Doxycyclin, Ceftriaxon - Gonorrhea | Phase 4 | Completed | Bulovka Hospital | 161 | 2021-04-01 | 2023-10-23 |
| A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years Yuxi Walvax MPV ACYW® vaccine, Sanofi Pasteur Menactra® vaccine - Neisseria Meningitides Meningitis | Phase 4 | Completed | Walvax Biotechnology Co., Ltd. | 260 | 2020-12-23 | 2023-07-07 |
| Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Ethiopia Azithromycin 500 mg, Multiple Micronutrient or Fortified Balanced Energy Protein Supplement, Placebo oral tablet 500 mg - Low Birthweight, Preterm Birth | Phase 4 | Withdrawn | Brigham and Women's Hospital | 2020-03-01 | 2020-08-17 | |
| Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP Doxycycline - HIV Infections, HIV/AIDS | Phase 4 | Completed | University of Washington | 449 | 2020-02-05 | 2024-07-10 |
| Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Doxycycline Hyclate Delayed-Release 200 mg - Gonorrhea, Chlamydia | Phase 4 | Completed | University of California, San Francisco | 641 | 2019-11-26 | 2024-07-12 |
| Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine Meningococcal Group B Vaccine - Neisseria Gonorrhoeae Infection | Phase 4 | Completed | University of North Carolina, Chapel Hill | 11 | 2019-10-09 | 2021-07-15 |
| Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Ciprofloxacin - Meningitis, Meningococcal | Phase 4 | Withdrawn | Epicentre | 2019-03-01 | 2019-08-14 | |
| Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population Bexsero® (meningitis B vaccine), Menveo® (meningitis ACWY vaccine) - Hiv, Meningitis, Meningococcal | Phase 4 | Unknown | St George's, University of London | 55 | 2019-02-21 | 2019-04-10 |
| Adolescent MenACWY Booster Study MenACWY-CRM, MenACWY-DT, MenACWY-TT - Meningococcal Disease, Invasive | Phase 4 | Completed | Canadian Immunization Research Network | 244 | 2018-09-20 | 2022-03-11 |
Showing 20 of 53. Sign in to see all of them.
Meningococcal Infections (30) · Meningitis, Meningococcal (16) · Gonorrhea (15) · Meningitis (15) · Chlamydia Infections (9) · Sexually Transmitted Diseases (8) · Syphilis (6) · Pneumococcal Infections (5) · Tetanus (4) · Whooping Cough (4) · Acquired Immunodeficiency Syndrome (3) · Diphtheria (3) · HIV Infections (3) · Homosexuality (2) · Premature Birth (2)
Bacterial Infections (53) · Bacterial Infections and Mycoses (53) · Gram-Negative Bacterial Infections (53) · Infections (53) · Nervous System Diseases (24) · Neuroinflammatory Diseases (24) · Urogenital Diseases (18) · Communicable Diseases (17) · Genital Diseases (17) · Central Nervous System Bacterial Infections (16) · Central Nervous System Diseases (16) · Central Nervous System Infections (16) · Meningitis, Bacterial (16) · Sexually Transmitted Diseases, Bacterial (14)
Meningococcal Vaccines (12) · 4CMenB vaccine (7) · Azithromycin (4) · Doxycycline (4) · Ceftriaxone (3) · Ciprofloxacin (3) · serogroup C meningococcal conjugate vaccine (3) · MenACWY (2) · PsACWY vaccine (2) · 13-valent pneumococcal vaccine (1) · Cefixime (1) · Gemifloxacin (1) · Gentamicins (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Injections (1)
Sanofi Pasteur, a Sanofi Company (8) · GlaxoSmithKline (6) · Epicentre (3) · Public Health England (3) · University of Washington (3) · CanSino Biologics Inc. (2) · Novartis (2) · St George's, University of London (2) · Bangrak STIs Center (1) · Brigham and Women's Hospital (1) · Bulovka Hospital (1) · CHU de Quebec-Universite Laval (1) · Canadian Immunization Research Network (1) · Centro Superior de Investigación en Salud Publica (1) · Chinese University of Hong Kong (1)
United States (13) · United Kingdom (7) · South Korea (4) · China (3) · Australia (2) · Germany (2) · Kenya (2) · Niger (2) · Philippines (2) · Belgium (1) · Benin (1) · Canada (1) · Czechia (1) · Denmark (1) · Hong Kong (1)
Elizabeth Coates, PhD (2) · Andrew J Pollard, BA, MBBS, FRCPCH, PhD (1) · Andrew J. Pollard, MBBS, FRCPCH, PhD (1) · Anne Luetkemeyer, MD (1) · Catherine Cosgrove, MBBS PhD (1) · Cherie Blaire, MD, PhD (1) · Dan Granoff, MD (1) · Dominique A Caugant, PhD (1) · Elizabeth Miller, BSc MBBS FFPHM FRCPath (1) · Filip Rob, MD, PhD (1) · Helen Marshall (1)
PMID 37018493, PMID 38118022, PMID 16567982, PMID 19048025, PMID 19091990, PMID 19906895, PMID 19927040, PMID 20010312, PMID 20375851, PMID 21191076, PMID 22421690, PMID 22927016, PMID 24417689, PMID 24922166, PMID 25031289, PMID 25344356, PMID 25590331, PMID 26164694, PMID 26165914, PMID 26340483, PMID 26542382, PMID 26691105, PMID 27038321, PMID 27310354, PMID 27338951, PMID 27485493, PMID 28287802, PMID 28566335, PMID 28646924, PMID 28707175, PMID 29229440, PMID 29944651, PMID 31023259, PMID 31377946, PMID 31634044, PMID 31971677, PMID 32268996, PMID 32447370, PMID 32712083, PMID 33439463, PMID 33587122, PMID 33835852, PMID 34143341, PMID 34392717, PMID 34852691, PMID 35441055, PMID 35710444, PMID 37088964, PMID 37401618, PMID 38234190
2017 (2), 2014 (1), R01AI068107 (1), R01AI143439 (1), R01AI145971 (1), R01AI179838 (1), R01MH074394 (1), R01MH074399 (1), UM2HD111076 (1), UM2HD111102 (1)